Ads
related to: sanofi genzyme stock
Search results
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
Zacks via Yahoo Finance· 2 years agoBioMarin Pharmaceutical BMRN reported second-quarter 2022 adjusted earnings of 59 cents per share,...
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
Zacks via Yahoo Finance· 2 years agoBioMarin Pharmaceutical BMRN reported adjusted earnings of 45 cents per share in third-quarter 2022,...
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
Zacks via Yahoo Finance· 3 months agoBioMarin Pharmaceutical BMRN reported fourth-quarter 2023 adjusted earnings per share of 49 cents,...
5 Examples of Hostile Takeovers That Actually Worked
GOBankingRates via Yahoo Finance· 2 years agoSpeaking to contemporary headlines, JetBlue Airways is currently maneuvering a hostile takeover of competition Spirit Airlines for $3.6 billion. Only...
TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
Zacks via Yahoo Finance· 1 year agoThe FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of...
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have...
5 Stocks Likely to Gain on Q4 Earnings Today After Market Close
Zacks via Yahoo Finance· 3 months agoWe have narrowed our search to five large-cap stocks that are poised to beat on earnings today after...
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
Zacks via Yahoo Finance· 2 years agoThe FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for...
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Barrons.com· 1 month agoBARRON'S COVER - MAIN Understanding the products from pharmaceutical companies could be the most...
BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut
Zacks via Yahoo Finance· 6 months agoBioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company...
